PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, prepares for advanced phase clinical trials with CF101. Can-Fite announced today the successful completion of long-term pre-clinical toxicology studies with its lead drug, CF101. Studies were in full GLP compliance with US FDA and EMEA requirements. The success of these studies will enable patients that participate in future clinical studies with Can-Fite's CF101 to take the drug for periods of 6-12 months or longer, as generally required in phase III clinical studies.
